{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Enrollment",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_2",
        "name": "CRU Admission 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_3",
        "name": "Diet Equilibration Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 2
      },
      {
        "id": "timing_4",
        "name": "Pretreatment Balance Measurement",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -4,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 3
      },
      {
        "id": "timing_5",
        "name": "CRU Re-admission 2",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 1
      },
      {
        "id": "timing_6",
        "name": "Dose Titration to 30mg/day",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_7",
        "name": "End of Study Visit",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_8",
        "name": "Zinc Washout Period",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -21,
        "relativeTo": "First Dose",
        "windowUpper": 0
      },
      {
        "id": "timing_9",
        "name": "Chelator Washout Period",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -4,
        "relativeTo": "First Dose",
        "windowUpper": 0
      },
      {
        "id": "timing_10",
        "name": "Experimental Therapy Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -90,
        "relativeTo": "Screening",
        "windowUpper": 0
      },
      {
        "id": "timing_11",
        "name": "Prescription Medication Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -14,
        "windowUpper": 0
      },
      {
        "id": "timing_12",
        "name": "Non-Prescription Medication Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "windowUpper": 0
      },
      {
        "id": "timing_13",
        "name": "Alcohol Abstinence",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": -48,
        "relativeTo": "First Dose",
        "windowUpper": 0
      },
      {
        "id": "timing_14",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_15",
        "name": "Post-dose Meal Delay",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "First Dose",
        "windowLower": 0
      },
      {
        "id": "timing_16",
        "name": "Pregnancy Test Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_17",
        "name": "ALXN1840 Washout",
        "type": "Within",
        "unit": "years",
        "instanceType": "Timing",
        "value": -1,
        "relativeTo": "First Dose",
        "windowUpper": 0
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Safety Review for Dose Titration",
        "instanceType": "Condition",
        "description": "Safety Review Committee (SRC) must review available safety data through Day 23 for each participant before titration to 30 mg/day.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "The Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval.",
        "text": "To ensure flexibility, the Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      },
      {
        "id": "cond_3",
        "name": "ALT/AST Elevation (Moderate)",
        "instanceType": "Condition",
        "description": "ALT or AST is > 3x ULN and <= 5x ULN.",
        "text": "ALT or AST > 3 × ULN and ≤ 5 × ULN"
      },
      {
        "id": "cond_4",
        "name": "ALT/AST Elevation (Severe)",
        "instanceType": "Condition",
        "description": "ALT or AST is > 5x ULN.",
        "text": "ALT or AST > 5 × ULN"
      },
      {
        "id": "cond_5",
        "name": "Hemoglobin Decrease",
        "instanceType": "Condition",
        "description": "Hemoglobin is < 10 g/dL or has a > 20% decrease from baseline.",
        "text": "Hemoglobin < 10 g/dL or > 20% ↓ from baseline"
      },
      {
        "id": "cond_6",
        "name": "Platelet Decrease",
        "instanceType": "Condition",
        "description": "Platelets are < 100,000/mm3 or have a > 30% decrease from baseline.",
        "text": "Platelets < 100,000/mm3 or > 30% ↓ from baseline"
      },
      {
        "id": "cond_7",
        "name": "Neutrophil Decrease",
        "instanceType": "Condition",
        "description": "Neutrophils have a > 30% decrease from baseline and are below the reference range.",
        "text": "> 30% ↓ from baseline Neutrophils below reference range at baseline"
      },
      {
        "id": "cond_8",
        "name": "Hy's Law Criteria",
        "instanceType": "Condition",
        "description": "Bilirubin is > 2x ULN accompanied by ALT > 3x ULN.",
        "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, indicative of liver injury"
      },
      {
        "id": "cond_9",
        "name": "Neurological Worsening",
        "instanceType": "Condition",
        "description": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_10",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Evidence of clinically significant acute psychiatric worsening.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Following the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for Moderate ALT/AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT or AST > 3x ULN and <= 5x ULN, temporarily interrupt dosing. Rechallenge at 15 mg QOD when ALT/AST < 2x ULN."
      },
      {
        "id": "trans_3",
        "name": "Dose Discontinuation for Severe ALT/AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT or AST > 5x ULN, discontinue ALXN1840."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Hemoglobin Decrease",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Hemoglobin < 10 g/dL or > 20% decrease from baseline, reduce dose to previous dose level or to 15 mg QOD."
      },
      {
        "id": "trans_5",
        "name": "Dose Reduction for Platelet Decrease",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Platelets < 100,000/mm3 or > 30% decrease from baseline, reduce dose to previous dose level or to 15 mg QOD."
      },
      {
        "id": "trans_6",
        "name": "Dose Reduction for Neutrophil Decrease",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Neutrophils > 30% decrease from baseline and below reference range, reduce dose to previous dose level or to 15 mg QOD."
      },
      {
        "id": "trans_7",
        "name": "Dose Interruption for Hy's Law Criteria",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN with ALT > 3x ULN, temporarily interrupt dosing. Rechallenge requires approval of the Alexion Medical Monitor."
      },
      {
        "id": "trans_8",
        "name": "Dose Modification for Neurological Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If there is evidence of neurologic worsening, the Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease)."
      },
      {
        "id": "trans_9",
        "name": "Intervention Discontinuation for Serious Hypersensitivity",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if a serious hypersensitivity reaction occurs."
      },
      {
        "id": "trans_10",
        "name": "Intervention Discontinuation for Severe Infection",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if a severe uncontrolled infection occurs."
      },
      {
        "id": "trans_11",
        "name": "Intervention Discontinuation for Disallowed Medication",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for use of disallowed medication."
      },
      {
        "id": "trans_12",
        "name": "Intervention Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for pregnancy or planned pregnancy."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretion Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor Termination of Study",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of Alexion."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point on Day 29 to titrate dose from 15 mg/day to 30 mg/day, contingent on favorable safety review of data through Day 23.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Dose Modification for Safety",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing decisions to modify, interrupt, or discontinue study drug based on safety monitoring for liver function, hematology, and neurological/psychiatric status.",
        "conditionIds": [
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8",
          "cond_9",
          "cond_10"
        ]
      }
    ],
    "summary": {
      "timingCount": 17,
      "conditionCount": 10,
      "transitionRuleCount": 12,
      "exitCount": 5
    }
  }
}